Data published in Molecular Diagnostics & Therapy demonstrate how Secarna’s powerful bioinformatics generate improved LNA-modified antisense oligonucleotide therapies
Antisense oligonucleotide candidate derived from Secarna Pharmaceuticals’ LNAplusTM platform has entered pre-clinical safety trials for the treatment of elevated blood lipids
Secarna Pharmaceuticals and Denali Therapeutics enter into research and option agreement to develop novel antisense therapies in the field of neurodegenerative diseases